☆ 4.3 Article

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

HEMASPHERE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa et al.

Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Jesus San-Miguel et al.

Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, daratumumab-based therapy reduces the risk of disease progression or death. MRD-negative status and sustained MRD negativity are associated with improved progression-free survival, and daratumumab-based therapy improves rates of MRD negativity lasting 6 or 12 months.

BLOOD (2022)

添加到收藏夹

Article Hematology

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Michele Cavo et al.

Summary: In this study, we explored the impact of minimal residual disease (MRD) on relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). The results showed that achieving complete response or better (>= CR) and MRD negativity were associated with improved progression-free survival (PFS) in both RRMM and TIE NDMM patients, regardless of the type of therapy or disease setting.

BLOOD (2022)

添加到收藏夹

Article Oncology

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Ruth M. de Tute et al.

Summary: This study found that MRD status at ASCT + 3 and ASCT + 9 is a powerful predictor of PFS and OS in patients with multiple myeloma. Lenalidomide maintenance therapy can increase the likelihood of converting from MRD-positive to MRD-negative. However, high-risk molecular features still have a negative impact on PFS and OS.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

Kara-Louise Royle et al.

Summary: This study is a multicenter, risk-adapted, response-guided, open-label, randomized controlled trial for patients with multiple myeloma. It includes different treatment strategies and adjusts the treatment based on the risk profile of the patients.

BMJ OPEN (2022)

添加到收藏夹

Article Medicine, General & Internal

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Paul G. Richardson et al.

Summary: In patients with newly diagnosed multiple myeloma, adding autologous stem-cell transplantation to triplet therapy (RVD) can prolong progression-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study

Benjamin A. Derman et al.

Summary: Treatment of newly diagnosed multiple myeloma (NDMM) with an Elo-KRd regimen has shown promising results, with high rates of stringent complete response (sCR) and/or MRD-negativity. Further evaluation is needed to determine the optimal treatment strategy and the role of autologous stem cell transplant (ASCT) in this setting.

JAMA ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Hematology

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Maria-Victoria Mateos et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Martin F. Kaiser et al.

BLOOD (2022)

添加到收藏夹

Article Hematology

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Ibai Goicoechea et al.

Summary: An analysis of patients with multiple myeloma revealed that undetectable measurable residual disease (MRD) predicts higher progression-free survival, and identified differences in MRD resistance mechanisms between patients with standard and high-risk cytogenetic abnormalities.

BLOOD (2021)

添加到收藏夹

Review Oncology

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Luciano J. Costa et al.

Summary: MRD assessment plays an increasingly important role in multiple myeloma clinical trials, but the heterogeneity in assessment and reporting methods poses challenges for data interpretation and study design. An international panel of investigators has reached consensus on including MRD in trials, recommended assessment time points, and analytical validation for MRD assays, as well as outlined parameters for reporting MRD results. The panel also provides guidance on incorporating newer approaches for residual disease detection.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

A Cost Impact Analysis of clonoSEQ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany

Stefan Walzer et al.

Summary: Cost-effectiveness analysis shows that MRD testing with ClonoSEQ (R) in maintenance therapy for multiple myeloma patients in Germany can save costs, improve treatment outcomes, and support the more efficient use of high-cost drugs by health insurance funds.

ONCOLOGY AND THERAPY (2021)

添加到收藏夹

Meeting Abstract Hematology

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Laura Rosinol et al.

BLOOD (2021)

添加到收藏夹

Article Hematology

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser et al.

Summary: The European LeukemiaNet MRD Working Party updated the 2018 MRD recommendations, including technical specifications and integrative assessments. They also proposed the use of MRD as a prognostic and surrogate endpoint for drug testing, as well as the clinical implications of MRD assessment in AML. Recommendations include technical requirements for flow cytometry and molecular MRD analysis, as well as reporting methods for MRD results.

BLOOD (2021)

添加到收藏夹

Review Hematology

Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

Karthik Ramasamy et al.

Summary: Despite the introduction of new therapies, multiple myeloma remains incurable and the treatment landscape is becoming increasingly complex. Relapsed refractory multiple myeloma presents a significant clinical challenge, with a highly heterogeneous patient population requiring careful consideration for treatment selection. Multiple treatment options are continually growing, with emerging novel therapies under clinical development.

BLOOD REVIEWS (2021)

添加到收藏夹

Article Oncology

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Herve Avet-Loiseau et al.

Summary: In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by more than 60% in the POLLUX and CASTOR trials. The use of daratumumab-based combinations resulted in higher rates of sustained MRD negativity compared to standard of care, leading to improved clinical outcomes and prolonged progression-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity

Kazuhito Suzuki et al.

Summary: Improving the immunological environment and eradicating minimal residual disease (MRD) are crucial for long-term survival in multiple myeloma patients. Treatment options such as immunomodulatory drugs, monoclonal antibodies, and stem cell transplantation are important in achieving these goals, but effective strategies for persistent MRD positivity need further research and analysis.

CANCERS (2021)

添加到收藏夹

Article Hematology

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Ana Jimenez-Ubieto et al.

BLOOD (2021)

添加到收藏夹

Article Oncology

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Kenneth C. Anderson et al.

Summary: The development of novel agents has enabled minimal residual disease (MRD) negativity in the treatment of multiple myeloma. Technologies such as bone marrow and liquid biopsy-based assays provide real-time clinical tools for the sensitive detection and monitoring of MRD. Clinicians are considering using MRD to inform real-world clinical care, but different disease settings present challenges that will need to be addressed through clinical trials.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Letter Oncology

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Joaquin Martinez-Lopez et al.

Summary: Making clinical decisions based on MRD results in MM patients can lead to improved outcomes, as stopping or changing treatment based on MRD status can result in prolonged PFS.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau et al.

Summary: The study showed that the addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.

LANCET (2021)

添加到收藏夹

Article Hematology

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

Benjamin Diamond et al.

Lancet Haematology (2021)

添加到收藏夹

Article Medicine, General & Internal

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Maria-Victoria Mateos et al.

LANCET (2020)

添加到收藏夹

Review Oncology

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma

Stefania Oliva et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Hematology

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees et al.

BLOOD (2020)

添加到收藏夹

Review Oncology

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches

Ioannis V. Kostopoulos et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Meletios Dimopoulos et al.

LANCET (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

Delphi Technique in Health Sciences: A Map

Marlen Niederberger et al.

FRONTIERS IN PUBLIC HEALTH (2020)

添加到收藏夹

Article Oncology

Multiple Myeloma, Version 3.2021

Shaji K. Kumar et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

添加到收藏夹

Article Hematology

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Nikhil C. Munshi et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Meeting Abstract Hematology

Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow- NGF) Vs. Next-Generation Sequencing

Hiroyuki Takamatsu et al.

BLOOD (2020)

添加到收藏夹

Article Medicine, General & Internal

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau et al.

LANCET (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study

Wendy Gidman et al.

ADVANCES IN THERAPY (2019)

添加到收藏夹

Article Oncology

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

A. Horwich et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Hematology

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

Nicholas J. Short et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

Article Oncology

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma

L. Rasche et al.

LEUKEMIA (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

Renato Bassan et al.

ADVANCES IN THERAPY (2019)

添加到收藏夹

Article Hematology

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Eirini Katodritou et al.

ANNALS OF HEMATOLOGY (2018)

添加到收藏夹

Article Hematology

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Gerrit J. Schuurhuis et al.

BLOOD (2018)

添加到收藏夹

Article Oncology

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update

Naren Ramakrishna et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

M. -V. Mateos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Meeting Abstract Hematology

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Francesca Gay et al.

BLOOD (2018)

添加到收藏夹

Article Oncology

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

P. Moreau et al.

LEUKEMIA (2017)

添加到收藏夹

Article Oncology

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Juan-Jose Lahuerta et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Barriers to clinical adoption of next-generation sequencing: a policy Delphi panel's solutions

Donna A. Messner et al.

PERSONALIZED MEDICINE (2017)

添加到收藏夹

Article Oncology

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis

Donald A. Berry et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Oncology

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Kenneth C. Anderson et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Review Hematology

Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL

Philip A. Thompson et al.

BLOOD (2016)

添加到收藏夹

Review Oncology

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

M. A. Dimopoulos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Deep Response in Multiple Myeloma: A Critical Review

Mariateresa Fulciniti et al.

BIOMED RESEARCH INTERNATIONAL (2015)

添加到收藏夹

Article Oncology

The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma

S. Robinson et al.

LEUKEMIA (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.